Saturday, 30 March 2024
Deciphera Pharmaceuticals Inc. Common Stock
09:48 | 31/1/18
Concord Register
Needle moving action has been spotted in Deciphera Pharmaceuticals Inc (DCPH) as shares are moving today on volatility -0.83% or -0.22 from the open.
more»
06:26 | 31/1/18
Post Analyst
As regular trading ended, Deciphera Pharmaceuticals, Inc. (DCPH) stock brought in a -$0.22 drop to $26.22. The day started at a price of $26.35 but then traded as high as $26.67 before giving part of the gains back.
more»
... important recent Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) news were published by: Businesswire.com which released: “Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in …” on January 04, 2018, also Globenewswire.
more»
00:15 | 31/1/18
Wall Street Morning
Technical analysis of Deciphera Pharmaceuticals, Inc. (DCPH) stock includes study of technical indicators and past trends.
more»
22:33 | 20/1/18
Frisco Fastball
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer ...
more»
01:00 | 5/1/18
Business Wire
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
more»
01:00 | 4/1/18
Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.
more»
01:00 | 19/12/17
GlobeNewswire
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
more»
01:00 | 29/11/17
GlobeNewswire
WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the European Medicines Agency ...
more»
01:00 | 21/11/17
GlobeNewswire
WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the presentation of data from its ...
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |